These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 1391015)

  • 21. Penicillin-insensitive pneumococci: isolation from patients with pneumonia.
    Perlino CA; Burleigh P
    South Med J; 1979 Jan; 72(1):20-2. PubMed ID: 32628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?
    Peterson LR
    Clin Infect Dis; 2006 Jan; 42(2):224-33. PubMed ID: 16355333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome.
    Bonnard P; Lescure FX; Douadi Y; Schmit JL; Jounieaux V; Laurans G; Eb F; Ducroix JP
    J Infect; 2005 Jul; 51(1):69-76. PubMed ID: 15979494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [beta-lactam-antibiotics in the treatment of community-acquired respiratory tract infections with penicillin-resistant pneumococci].
    Brauers J; Ewig S; Kresken M
    Pneumologie; 2002 Oct; 56(10):605-9. PubMed ID: 12375222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients].
    Stephan C; Just-Nübling G; Franck S; Bickel M; Shah PM; Babacan E; Staszewski S
    Med Klin (Munich); 2008 Feb; 103(2):69-74. PubMed ID: 18270662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults.
    Martínez E; Miró JM; Almirante B; Aguado JM; Fernandez-Viladrich P; Fernandez-Guerrero ML; Villanueva JL; Dronda F; Moreno-Torrico A; Montejo M; Llinares P; Gatell JM;
    Clin Infect Dis; 2002 Jul; 35(2):130-9. PubMed ID: 12087518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology of invasive pneumococcal disease in Kumasi, Ghana.
    Holliman RE; Liddy H; Johnson JD; Adjei O
    Trans R Soc Trop Med Hyg; 2007 Apr; 101(4):405-13. PubMed ID: 17126867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of community-acquired pneumonia--treatment].
    Andersen LV; Brock B; Jakobsen P; Nielsen LP
    Ugeskr Laeger; 2008 Jan; 170(3):127-30. PubMed ID: 18208726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Endocarditis due to penicillin-sensitive and -resistant pneumococci: the current perspectives on the disease].
    Aguado JM; Casillas A; Lizasoaín M; Lumbreras C; Peña C; Martín-Durán R; Fernández-Viladrich P; Fernández-Guerrero ML; Noriega AR
    Med Clin (Barc); 1993 Mar; 100(9):325-8. PubMed ID: 8455409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program.
    Castanheira M; Gales AC; Mendes RE; Jones RN; Sader HS
    Clin Microbiol Infect; 2004 Jul; 10(7):645-51. PubMed ID: 15214878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
    Knudsen JD
    Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
    Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Question 3: can pneumonia caused by penicillin-resistant Streptococcus pneumoniae be treated with penicillin?
    Clifford V; Tebruegge M; Vandeleur M; Curtis N
    Arch Dis Child; 2010 Jan; 95(1):73-7. PubMed ID: 20040690
    [No Abstract]   [Full Text] [Related]  

  • 38. Community-acquired pneumonia due to penicillin-resistant pneumococci.
    Feldman C; Kallenbach JM; Miller SD; Thorburn JR; Koornhof HJ
    N Engl J Med; 1985 Sep; 313(10):615-7. PubMed ID: 4022048
    [No Abstract]   [Full Text] [Related]  

  • 39. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started.
    Mufson MA; Chan G; Stanek RJ
    Am J Med Sci; 2007 Mar; 333(3):161-7. PubMed ID: 17496734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with beta-lactam monotherapy.
    Garau J; Aguilar L; Rodríguez-Créixems M; Dal-ré R; Pérez-Trallero E; Rodríguez M; Bouza E
    J Chemother; 1999 Aug; 11(4):266-72. PubMed ID: 10465128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.